Literature DB >> 16441426

Tetramer-blocking assay for defining antigen-specific cytotoxic T lymphocytes using peptide-MHC tetramer.

Hiroshi Yokouchi1, Kenji Chamoto, Daiko Wakita, Daisuke Noguchi, Koichi Yamazaki, Hirotoshi Dosaka-Akita, Masaharu Nishimura, Hiroaki Ikeda, Takashi Nishimura.   

Abstract

Peptide-MHC tetramers have been engineered to allow accurate detection of antigen-specific cytotoxic C lymphocytes (CTL) by flow cytometry. Here, we propose a novel use for peptide-MHC tetramers in the specific and sensitive analysis of the cytotoxic function of antigen-specific CTL by blocking MHC-restricted antigen-specific cytotoxicity. We found that pretreatment of ovalbumin (OVA)-specific CD8(+) CTL (OT-1 CTL), derived from OT-1 T-cell receptor (TCR)-transgenic mice, with OVA(257-264) peptide-H-2K(b) tetramer caused a marked inhibition of the cytotoxicity against OVA-expressing EG-7 tumor cells. OVA(257-264) peptide-H-2K(b) tetramer did not block the cytotoxicity mediated by 2C mouse (H-2(b))-derived CD8(+) CTL, which recognize allo (H-2L(d)) antigens. Moreover, OT-I CTL activity was not inhibited by an irrelevant HBV(208-216) peptide-H-2K(b) tetramer. These results indicate that the blocking of CTL activity with peptide-MHC tetramer was caused by interference with the interaction between the TCR and H-2K(b)-OVA(257-264) peptide complex, but not with the CD8-MHC class I interaction. The blocking activity of OVA(257-264) peptide-H-2K(b) tetramer was reversible because OT-I CTL pretreated with the tetramer recovered their cytotoxicity after culturing with interleukin-2 for 24 h. The same results were also demonstrated in freshly isolated, in vivo-primed OT-1 CTL sorted by the tetramer. These results demonstrate that peptide-MHC tetramer is a useful tool for defining MHC-restricted antigen-specific CTL function. Moreover, our finding implies that the measurement of CTL activity immediately after tetramer-guided sorting is not a suitable method for evaluating the function of in vivo-induced tetramer-positive CTL. We believe that the tetramer-blocking assay presented here will be useful for functionally monitor the induction of MHC-restricted antigen-specific CTL during vaccination therapy against tumor and infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16441426     DOI: 10.1111/j.1349-7006.2006.00149.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  7 in total

1.  Dab2, a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy.

Authors:  Md Selim Ahmed; Se Eun Byeon; Yideul Jeong; Mohammad Alam Miah; Md Salahuddin; Yoon Lee; Sung-Soo Park; Yong-Soo Bae
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

2.  Identification of H-2d restricted T cell epitope of foot-and-mouth disease virus structural protein VP1.

Authors:  Xin-Sheng Liu; Yong-Lu Wang; Yong-Guang Zhang; Yu-Zhen Fang; Li Pan; Jian-Liang Lu; Peng Zhou; Zhong-Wang Zhang; Shou-Tian Jiang
Journal:  Virol J       Date:  2011-09-07       Impact factor: 4.099

3.  Identification of apoB-100 Peptide-Specific CD8+ T Cells in Atherosclerosis.

Authors:  Paul C Dimayuga; Xiaoning Zhao; Juliana Yano; Wai Man Lio; Jianchang Zhou; Peter M Mihailovic; Bojan Cercek; Prediman K Shah; Kuang-Yuh Chyu
Journal:  J Am Heart Assoc       Date:  2017-07-15       Impact factor: 5.501

4.  Toll-like receptor 3 signal augments radiation-induced tumor growth retardation in a murine model.

Authors:  Sumito Yoshida; Hiroaki Shime; Yohei Takeda; Jin-Min Nam; Ken Takashima; Misako Matsumoto; Hiroki Shirato; Masanori Kasahara; Tsukasa Seya
Journal:  Cancer Sci       Date:  2018-03-25       Impact factor: 6.716

5.  Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.

Authors:  Yohei Takeda; Sumito Yoshida; Ken Takashima; Noriko Ishii-Mugikura; Hiroaki Shime; Tsukasa Seya; Misako Matsumoto
Journal:  Cancer Sci       Date:  2018-06-16       Impact factor: 6.716

6.  Anti-oxidative Amino Acid L-ergothioneine Modulates the Tumor Microenvironment to Facilitate Adjuvant Vaccine Immunotherapy.

Authors:  Sumito Yoshida; Hiroaki Shime; Misako Matsumoto; Masanori Kasahara; Tsukasa Seya
Journal:  Front Immunol       Date:  2019-04-04       Impact factor: 7.561

7.  Combination tumor immunotherapy with radiotherapy and Th1 cell therapy against murine lung carcinoma.

Authors:  Hiroshi Yokouchi; Kenji Chamoto; Daiko Wakita; Koichi Yamazaki; Hiroki Shirato; Tsuguhide Takeshima; Hirotoshi Dosaka-Akita; Masaharu Nishimura; Zhang Yue; Hidemitsu Kitamura; Takashi Nishimura
Journal:  Clin Exp Metastasis       Date:  2007-07-25       Impact factor: 4.510

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.